Five day primaquine therapy—an evaluation of radical curative activity against vivax malaria infection

Peter G. Contacos Section on Primate Malaria, Laboratory of Parasitic Diseases, National Institutes of Health, Chamblee, Georgia 30341

Search for other papers by Peter G. Contacos in
Current site
Google Scholar
PubMed
Close
,
G. Robert Coatney Section on Primate Malaria, Laboratory of Parasitic Diseases, National Institutes of Health, Chamblee, Georgia 30341

Search for other papers by G. Robert Coatney in
Current site
Google Scholar
PubMed
Close
,
William E. Collins Section on Primate Malaria, Laboratory of Parasitic Diseases, National Institutes of Health, Chamblee, Georgia 30341

Search for other papers by William E. Collins in
Current site
Google Scholar
PubMed
Close
,
Peter E. Briesch Section on Primate Malaria, Laboratory of Parasitic Diseases, National Institutes of Health, Chamblee, Georgia 30341

Search for other papers by Peter E. Briesch in
Current site
Google Scholar
PubMed
Close
, and
Marvin H. Jeter Section on Primate Malaria, Laboratory of Parasitic Diseases, National Institutes of Health, Chamblee, Georgia 30341

Search for other papers by Marvin H. Jeter in
Current site
Google Scholar
PubMed
Close
Restricted access

The radical curative efficacy of the 5-day primaquine regimen for vivax malaria was assessed in nonimmune volunteers infected with a West Pakistan strain of Plasmodium vivax. Treatment of each primary attack was with chloroquine, 1,500 mg base followed by primaquine, 15 mg base daily for 5 consecutive days. There was a 100% failure rate of radical cure for the 5-day primaquine regimen. Data on the pattern of relapse activity for this strain are included.

Author Notes

Formerly Head, Section on Primate Malaria, Laboratory of Parasitic Diseases, National Institutes of Health, Atlanta-Chamblee, Georgia.

Save